{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhu X"],"funding":["Expert Workstation for Jingcheng Dong in Yunnan Province"],"pagination":["6842530"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9626231"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2022"],"pubmed_abstract":["<h4>Background</h4>Cycloastragenol (CAG) has been reported to alleviate airway inflammation in ovalbumin- (OVA-) induced asthmatic mice. However, its specific mechanisms remain unclear.<h4>Objective</h4>This study is aimed at investigating the effects of CAG on asthma, comparing its efficacy with dexamethasone (DEX), and elucidating the mechanism of CAG's regulation.<h4>Methods</h4>The asthma mouse model was induced by OVA. CAG at the optimal dose of 125 mg/kg was given every day from day 0 for 20-day prevention or from day 14 for a 7-day treatment. We observed the preventive and therapeutic effects of CAG in asthmatic mice by evaluating the airway inflammation, AHR, and mucus secretion. Lung proteins were used for TMT-based quantitative proteomic analysis to enunciate its regulatory mecha"],"journal":["Oxidative medicine and cellular longevity"],"pubmed_title":["TMT-Based Quantitative Proteomic Analysis Reveals Downregulation of ITGAL and Syk by the Effects of Cycloastragenol in OVA-Induced Asthmatic Mice."],"pmcid":["PMC9626231"],"funding_grant_id":["82174170","21S21902500","20210101"],"pubmed_authors":["Ruan Z","Li C","Chen M","Zhu H","Zhou Y","Wei Y","Yu H","Huang X","Dong J","Zhu X","Liu B","Xu W","Shi H","Sun J"],"additional_accession":[]},"is_claimable":false,"name":"TMT-Based Quantitative Proteomic Analysis Reveals Downregulation of ITGAL and Syk by the Effects of Cycloastragenol in OVA-Induced Asthmatic Mice.","description":"<h4>Background</h4>Cycloastragenol (CAG) has been reported to alleviate airway inflammation in ovalbumin- (OVA-) induced asthmatic mice. However, its specific mechanisms remain unclear.<h4>Objective</h4>This study is aimed at investigating the effects of CAG on asthma, comparing its efficacy with dexamethasone (DEX), and elucidating the mechanism of CAG's regulation.<h4>Methods</h4>The asthma mouse model was induced by OVA. CAG at the optimal dose of 125 mg/kg was given every day from day 0 for 20-day prevention or from day 14 for a 7-day treatment. We observed the preventive and therapeutic effects of CAG in asthmatic mice by evaluating the airway inflammation, AHR, and mucus secretion. Lung proteins were used for TMT-based quantitative proteomic analysis to enunciate its regulatory mecha","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-28T21:27:01.179Z","creation":"2025-04-05T14:54:29.781Z"},"accession":"S-EPMC9626231","cross_references":{"pubmed":["36329800"],"doi":["10.1155/2022/6842530"]}}